

XARANETIDE CONCUSSION DATA SELECTED FOR ORAL PRESENTATION AT INTERNATIONAL NEUROTRAUMA CONGRESS

Perth, Australia; 15 September, 2026 - Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a biotechnology company developing novel therapeutics to reduce brain tissue death after brain injury, is pleased to announce that its recent preclinical concussion study¹ has been selected for **oral presentation at the 2026 Meeting of the International NeuroTrauma Society (INTS)**, being held in Cartagena, Colombia in October 2026.

The presentation titled ***A Single Low Dose of R18D is Neuroprotective after Repeated Mild Traumatic Brain Injury*** will be delivered by Dr Chidozie Anyaegbu, Lead of the Preclinical Neurotrauma Research Program and Research Fellow at Curtin University Faculty of Health Sciences, who lead the study.

The study was conducted by researchers from Curtin University and the Perron Institute for Neurological and Translational Science as part of Argenica's Cooperative Research Centre Project.

As previously announced¹, the study demonstrated that a **single low dose of xaranetide (R18D; ARG-007)** administered intravenously 30 minutes following a second mild traumatic brain injury significantly reduced markers of:

- neuroinflammation, including GFAP and Iba1;
- oxidative stress, including MnSOD; and
- axonal injury, including NF-L.

The effects were observed across multiple brain regions, including the cortex, corpus callosum, dentate gyrus and ventral tegmental area, and were sustained to Day 11 following injury.

The findings provide further preclinical evidence of xaranetide's neuroprotective activity following traumatic brain injury and support continued investigation of the drug across a range of acute neurological injuries. They complement Argenica's existing preclinical TBI program and its lead clinical development program in acute ischaemic stroke.

Dr Liz Dallimore, Managing Director of Argenica, commented: "Selection of these data for an oral presentation at the International NeuroTrauma Society meeting is an important recognition of the scientific interest in our concussion program."

¹ ASX Announcement dated 16 July, 2026 "ARG-007 (xaranetide) shows significant neuroprotection in preclinical concussion study"

Importantly, the study demonstrated that a single low dose of xaranetide administered after repeated mild traumatic brain injury produced sustained effects across multiple markers of secondary brain injury.

Together with our broader traumatic brain injury and stroke research, these findings continue to build the evidence supporting xaranetide as a potential neuroprotective treatment across acute neurological injuries.”

This announcement has been approved for release by the Managing Director of Argenica.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica Therapeutics Limited (ASX: AGN) is a clinical-stage biotechnology company developing innovative neuroprotective therapeutics to improve outcomes for patients following stroke and other acute neurological injuries. The Company’s lead drug candidate, ARG-007, is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event. With a strong scientific foundation and a clear clinical development pathway, Argenica is focused on advancing novel treatments that have the potential to significantly improve patient recovery and transform the standard of care in acute neurology.

For personal use only